ANTIOXIDANTS & REDOX SIGNALING Volume 13, Number 9, 2010

Mary Ann Liebert, Inc.

DOI: 10.1089/ars.2009.2949

Scavenging of Reactive Oxygen Species in Mitochondria Induces Myofibroblast Differentiation

Ekaterina N. Popova, Olga Y. Pletjushkina, Vera B. Dugina, Lidia V. Domnina, Olga Y. Ivanova, Denis S. Izyumov, Vladimir P. Skulachev, and Boris V. Chernyak

Abstract

The goal of this study was to investigate the possible role of reactive oxygen species (ROS) in signaling, in modulation of the cytoskeleton, and in differentiation of fibroblasts. For this purpose, we have applied a novel mitochondria-targeted antioxidant: plastoquinone conjugated with decyltriphenylphosphonium (SkQ1). This antioxidant at nanomolar concentration prevented ROS accumulation and cell death induced by H_2O_2 in fibroblasts. We found that scavenging of ROS produced by mitochondria activated the Rho/ROCK/LIMK signaling pathway that was followed by phosphorylation of cofilin and stabilization of actin stress fibers. The mitochondria-targeted antioxidant induced differentiation of human subcutaneous fibroblasts to myofibroblasts as revealed by expression of fibronectin isoform (EDA-FN) and smooth muscle actin (α -SMA). This effect was shown to be mediated by transforming growth factor β 1 (TGF β 1), which was activated by matrix metalloprotease 9 (MMP9) in the culture medium. Scavenging of ROS stimulated secretion of MMP9 rather than its processing. The same effect was achieved by the nontargeted antioxidant Trolox at higher concentration, but the thiol antioxidant N-acetylcysteine (NAC) inhibited MMP activity and was not able to induce myofibroblast differentiation. The myofibroblast phenotype was supported due to autocrine TGF β 1-dependent stimulation after removal of SkQ1. It is concluded that ROS scavenging in mitochondria induces TGF β 1-dependent myofibroblast differentiation. *Antioxid. Redox Signal.* 13, 1297–1307.

Introduction

IFFERENTIATION OF FIBROBLASTS into myofibroblasts is an important stage in wound healing and tissue regeneration. However, deregulation of differentiation and excessive accumulation of myofibroblasts can cause hypertrophic scar formation and fibrosis in various tissues (17, 20). Myofibroblasts have developed bundles of actin fibrils (stress fibers) containing smooth muscle actin (α -SMA). Stress fibers are connected with supermature focal adhesions attached to the EDA isoform of fibronectin (EDA-FN), which determine tight adhesion of myofibroblasts to extracellular matrix (ECM). Myofibroblasts modulate the key properties of the ECM—the spectrum of expressed collagens and fibronectins and the active matrix proteases. These changes result in more pronounced adhesion and contractility of myofibroblasts compared to fibroblasts. These features are important for wound healing and scar formation.

Transforming growth factor $\beta 1$ (TGF $\beta 1$) is a key factor inducing myofibroblast differentiation during wound healing as well as in pathological fibrosis. Exogenous TGF $\beta 1$ induces formation of myofibroblasts in different fibroblast cultures.

Myofibroblast differentiation is also regulated by other cytokines, chemokines, and adhesion molecules (EGF, FGF-2, IL-1, IFN- γ). When differentiation is induced by these factors, it probably also depends on active TGF β 1 (19). Expression of α -SMA and other specific myofibroblasts proteins (EDA-FN, collagen I, etc) depends on TGF β 1-induced stimulation of the SMAD pathway in combination with other pathways (13, 36). Moreover, RhoA pathways can be rapidly activated by TGF β 1 by SMAD-independent mechanisms (13). These pathways are known to be involved in cytoskeleton remodeling.

TGF β 1 is secreted by the cell as a large latent complex (TGF β -LAP/LTBP) covalently bound to the ECM (3). Physiological activation of TGF β 1 can be induced by proteolytic cleavage of this latent complex by plasmin or metalloproteases (MMP2 and MMP9). However, cleavage-independent activation is also possible. It is mediated by the interaction of the complex with thrombospondin-1 or integrins, as well as low pH or oxidative stress (3, 39, 40).

Reactive oxygen species (ROS) function as second messengers for signal transduction induced by many cytokines (including TGF β 1, EGF, PDGF), leading to proliferation, differentiation, or cell death (10, 11, 37). Mitochondria are one of

the major sources of ROS in the cell and can, in principle, contribute to regulation of various signaling pathways (11, 18, 29-31), but it remains unclear whether mitochondrial ROS are specifically required for this regulation. Studies in this direction are greatly hindered by the absence of specific tools for measurement and modification of ROS production in mitochondria. Recently, mitochondria-targeted antioxidants were developed and applied to studies of cell signaling. The first mitochondria-targeted antioxidant MitoQ was synthesized and studied by Murphy and coworkers (23). A novel group of mitochondria-targeted antioxidants called SkQs was recently developed in our laboratory. SkQ1 [10-(6'-plastoquinonyl) decyltriphenylphosphonium] was found to be more efficient as an antioxidant than MitoQ in artificial membranes, isolated mitochondria, cells in culture, and some animal models (1, 4, 5, 7, 27, 32, 35). Using SkQ1, we have shown that ROS produced by mitochondria are critical for fragmentation of mitochondrial reticulum and apoptosis induced by exogenous hydrogen peroxide or by inhibitors of mitochondrial functions (4). It was found that mitochondrial ROS are involved in cytoskeleton remodeling in fibroblasts and epithelial cells during neoplastic transformation in vitro and in progression of some tumors in vivo (1). In the present study, we have applied SkQ1 and some other antioxidants to studies on fibroblast-to-myofibroblast differentiation. We show for the first time that scavenging of mitochondrial ROS strongly stimulates this differentiation.

Materials and Methods

Cells

Normal human subcutaneous diploid fibroblasts (HSCF, Cell Culture Collection, Institute of Medical Genetics, Russian Academy of Medical Sciences, Moscow) were used. Cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) (Gibco, Carlsbad, CA) supplemented with 10% FBS (HyClone, San Jose, CA) at 37°C with 5% CO2. Cells between 5–10 passages were used for experiments. It was found that the level of α -SMA and EDA-FN (markers of myofibroblasts) was very low in these cells. Some spontaneous differentiation of fibroblasts was observed at later passages.

Accumulation of SkQ1 in mitochondria

To study the localization of SkQ1 in cells, we used its fluorescent analog SkQR1 [10-(6'-plastoquinonyl) decylrhodamine-19], where the triphenylphosphonium cationic group is replaced by rhodamine-19 (4). Mitochondria were visualized with MitoTracker Green (Molecular Probes, Eugene, OR). Cells were treated with SkQR1 (20 nM, 2 h) and MitoTracker Green (300 nM, 30 min, 37°C) and analyzed using an Axiovert microscope(Carl Zeiss) equipped with a Neofluar $100 \times NA$ 1.3 objective. The thickness of the optical slices was about 1 μ m.

Measure of ROS production

SkQ1-treated cells were incubated with 200 μ M H₂O₂ in the medium. ROS production was measured after loading the cells with 5 μ M CM-DCF-DA (Molecular Probes) for 15 min at 37°C, as described earlier (1, 22). Cells were analyzed with an FC 500 cytofluorimeter (Beckman Coulter, Brea, CA).

Cell viability

After incubation with antioxidants, the cells were treated with H₂O₂ for 24 h, and cell viability was determined with CellTiterBlue reagent (Promega Corporation, Madison, WI). Intensity of fluoresce was measured with a Fluoscan Ascent fluorimeter (Thermo Electron Corporation, San Jose, CA).

Western blotting analysis

Cell extracts were prepared as described earlier (1), and protein concentration of the extracts was determined using the RC DC protein assay system (BioRad, Hercules, CA). Protein samples (5–10 μg) were separated on SDS-polyacrylamide gel and transferred to PVDF membrane (Amersham Biosciences, Piscataway, NJ). The membrane was probed with antibodies specific to α -SMA (Sigma), EDA-FN (a kind gift of Dr. Zardi (33)), SMAD2, phospho-SMAD2, and cofilin or phospho-cofilin (Cell Signaling Technology, Danvers, MA). Antibodies against α-tubulin or vimentin (Sigma) were used as a loading control. Membranes were treated with HRPconjugated secondary antibody (Sigma) and developed with ECL chemiluminescence reagents (Amersham) according to the manufacturer's protocol. ImageJ software (National Institutes of Health, http://rsb.info.nih.gov/ij/) was used for densitometric analysis of bands.

Immunostaining and morphometry

Cells were fixed with 2% paraformaldehyde followed by 5 min treatment with methanol at -20° C for immunofluorescence staining or with 0.2% Triton X-100 for actin staining with phalloidin-TRITC (Sigma). Antibodies against α -SMA, actin, vinculin (Sigma), and EDA-FN were used. Goat antimouse antibodies conjugated with Alexa-488 (Molecular Probes) and TRITC-conjugated antibodies against rabbit immunoglobulins (Jackson Labs, Bar Harbor, ME) were used as secondary antibodies. Images were acquired using an Axiovert microscope equipped with objectives $20\times$ (dry) and $100\times$ (oil immersion Neofluar) (Carl Zeiss, Jena, Germany). The ImageJ software was used for morphometry. Elongation index was calculated as \log_2 (major radii/minor radii) (16).

Zymography

Zymography of MMP activities were measured as described earlier (9, 24). Electrophoresis was performed on samples (30 μ l culture medium per lane) at 4°C in 7.5% polyacrylamide gels containing 10% SDS and gelatin (1 mg/ml) under nonreducing conditions and without boiling of samples. The ImageJ software was used for densitometric analysis of bands.

ELISA

For TGF β 1 detection, culture medium was collected and immediately analyzed by sandwich ELISA as recommended by the manufacturer's instruction (R&D Systems, Minneapolis, MN). Latent TGF β 1 in the medium was activated by acidification to measure total TGF β 1. The recombinant human soluble receptor II of TGF β 1 (TGF β RII) (R&D Systems) was used as a capture reagent in combination with biotinylated TGF β 1 polyclonal detection antibody (R&D Systems) to measure active TGF β 1.

Statistical assay

Statistica 6.0 software was used for statistical analyses. Data presented as bar graphs are means \pm SEM. Sample size: $N \ge 3$ for Western blot analysis and zymography, $N \ge 500$ for morphometry, $N \ge 15$ for ELISA. Statistical analysis was performed using Student's t-test. The p values <0.05 (*), <0.01 (**), and <0.001 (***) are considered as statistically significant.

Results

SkQ1 inhibits oxidative stress and cell death in HSCF

SkQ1 has demonstrated very high antioxidant efficiency in model systems and isolated mitochondria (5). In experiments with HeLa cells, it was shown that SkO1 and SkOR1 accumulated in mitochondria and prevented H₂O₂-induced apoptosis at nanomolar concentration (4). Cellular localization and antioxidant activity of SkQ were analyzed in the HSCF model to verify these observations. SkQR1, a fluorescent SkQ analog, was selectively accumulated in mitochondria of HSCF as shown by colocalization with MitoTracker Green (Fig. 1A). When oxidative stress was induced in HSCF by exogenous H₂O₂, a secondary delayed production of endogenous ROS was detected, which later decreased to the background level. Pretreatment of the cells with SkQ1 (2 nM) completely abolished this effect of H₂O₂ (Fig. 1B). SkQ1 and SkQR1 also prevented decrease in cell viability induced by H₂O₂, and the maximal protection level was observed at 2 nM concentration of these antioxidants (Fig. 1C). It was found here that SkQ1 induced activation of TGF β 1 (see below) which could resulted in some cell resistance against apoptogenic stimuli. However, in control experiments, 24h incubation of fibroblasts with recombinant TGF β 1 did not affect H₂O₂-induced cell death (not shown). C₁₂TPP, the SkQ analog lacking the antioxidant (plastoquinone) moiety, failed to preserve viability of H₂O₂treated fibroblasts (Fig. 1C). The protonophorous uncoupler FCCP, which depolarizes the inner mitochondrial membrane, prevented accumulation of SkQR1 in mitochondria as well as the protective action of SkQ1 and SkQR1 (not shown). The extremely high efficiency of mitochondria-targeted antioxidant and the effect of FCCP indicate that under oxidative stress the mitochondrion is the major source of secondary ROS causing loss of cell viability.

SkQ1 induces differentiation of fibroblasts into myofibroblasts

Prolonged incubation of HSCF with SkQ1 induced dramatic changes in cell morphology. The area occupied by cells on the substrate was doubled, while their elongation index was decreased (Fig. 2). The changes in morphology were accompanied by a significant increase in number and thickness of actin stress fibers (Fig. 2A). Accumulation of the stress fibers was detected at 12-24 h and continued for 3-5 days after addition of SkQ1. Lengthening of vinculin-positive focal contacts at the ends of actin fibers was observed, indicating maturation of the focal adhesions (Fig. 3). These effects on cell morphology remained for at least 7 days after removal of SkQ1. The effects of SkQ1 were mediated by its antioxidant activity, since C₁₂TPP was completely ineffective (Fig. 2B). Accumulation of the antioxidant in mitochondria was critical for the observed action, and its uncharged analog decylplastoquinone (DPQ) was ineffective. Depolarization of the mi-




FIG. 1. SkQ is specifically accumulated in mitochondria of HSCF and prevents H_2O_2 -induced ROS generation and cell death. (A) HSCF were stained with SkQR1 (20 nM, 2 h) and MitoTracker Green (300 nM, 30 min) (fluorescent and phase contrast microscopy), bar 5 μ m; (B) HSCF were incubated with SkQ1 (20 nM, 1 day or 7 days), then 200 μ M H_2O_2 was added and ROS production was measured using CM-DCF-DA (flow cytometry); (C) cells were incubated for 24 h with SkQ1, SkQR1, or C_{12} TPP, then 600μ M H_2O_2 was added.

tochondrial membrane induced by the protonophorous uncoupler FCCP prevented electrophoretic accumulation of SkQ1 in mitochondria and abolished its effects on cell morphology. In control experiments, FCCP did not induce significant changes in the fibroblast morphology and did not prevent spreading of the cells induced by TGF β 1 (the role of




FIG. 2. Effects of SkQ1 on HSCF cell area, elongation, and actin cytoskeleton. HSCF were treated with $20\,\mathrm{nM}$ SkQ1, $20\,\mathrm{nM}$ C₁₂TPP, $20\,\mathrm{nM}$ DPQ, $1\,\mu\mathrm{M}$ FCCP, $200\,\mu\mathrm{M}$ Trolox, $5\,\mathrm{mM}$ NAC, or $5\,\mathrm{ng}/\mathrm{ml}$ TGF $\beta1$ for 7 days. (A) Actin was stained with Phalloidin-TRITC. Bar, $10\,\mu\mathrm{m}$; (B) analysis of cell area; here and below, $c=\mathrm{control}$ (no additions); (C) analysis of cell elongation.

TGF β 1 is explained below), indicating that depolarization of mitochondria did not interfere with the transitions of fibroblast phenotype. The classical antioxidants Trolox (a watersoluble analog of vitamin E) and N-acetylcysteine (NAC) induced similar changes in morphology and cytoskeleton of fibroblasts (Fig. 2B), but only at much higher concentrations (0.1 mM and 5 mM, respectively), confirming the key role of mitochondrial ROS as determinants of fibroblast morphology.

The changes in HSCF induced by SkQ1 made their phenotype similar to that ascribed to myofibroblasts (15, 19, 20). We analyzed expression of the major myofibroblast markers EDA-FN and α -SMA. The appearance of EDA-FN was more pronounced after 1–3 days of treatment with SkQ1. The expression of α -SMA became detectable on days 3–4 and well-

pronounced on days 5–7 of the treatment (Fig. 4). EDA-FN formed a typical network in the extracellular matrix, and α -SMA was incorporated in stress fibers. The same effect of expression of myofibroblast differentiation markers was observed after incubation with 0.1 mM Trolox (Fig. 4C), but NAC was ineffective.

The major mechanism of stress fiber stabilization is related to phosphorylation and inactivation of cofilin (8). This protein interacts with F-actin, preventing formation of the fibrils. Incubation with 20 nM SkQ1 induced phosphorylation of cofilin (Fig. 5). A significant increase in cofilin phosphorylation was observed at 2–4 h and remained high on 12 h of treatment with SkQ1, when accumulation of the stress fibers was observed. Trolox and NAC also induced phosphorylation of cofilin, but




FIG. 3. Effect of SkQ1 on adhesive contacts of HSCF. Cells were incubated with 20 nM SkQ1 for 7 days. Actin stress fibers and vinculin focal adhesions are shown. Bar, $5 \mu m$.




FIG. 4. SkQ1 induces expression of myofibroblast markers in HSCF cell culture. HSCF were treated as in Figure 2 and with TGF β 1RI kinase inhibitor II (230 nM) for 7 days. (A) Actin and α-SMA are shown; (B) staining with antibodies to EDA-FN; Bar, 15 μm; (C) expressions of α-SMA and EDA-FN (Western blotting; vimentin was used as a loading control).

at concentrations 10,000 or 250,000 times higher, respectively (Fig. 5). LIMK1/2 is the major kinase phosphorylating cofilin in fibroblasts, and this kinase can be activated via phosphorylation of Thr^{508/505} by Rho-dependent kinase ROCK (8, 38). We analyzed activation of LIMK1/2 using phosphospecific antibodies and demonstrated rapid phosphorylation of LIMK1/2 after treatment with SkQ1 (Fig. 5A). A specific inhibitor of ROCK, HA-1077, decreased the basal level of cofilin phosphorylation and inhibited phosphorylation of cofilin induced by SkQ1 and the other antioxidants (Fig. 5B). These




FIG. 5. SkQ1 induces Rho-dependent phosphorylation of LIMK1/2 and cofilin. (A) HSCF were incubated with 20 nM SkQ1, and phosphorylation of LIMK1/2 and cofilin were detected in parallel samples; (B) HSCF were incubated with 20 nM SkQ1, 5 mM NAC, 5 ng/ml TGF β 1, 10 μM Rho kinase (ROCK) inhibitor HA-1077, or 100 ng/ml soluble TGF β 1 receptor for 15 h (Western blotting; tubulin was used as a loading control).

data indicate that scavenging of ROS produced in mitochondria activates Rho-dependent signaling.

SkQ1-induced differentiation of fibroblasts is mediated by TGF_{\beta}1 activation

We suggest that the effects of SkQ1 are mediated by TGF β 1, a major inducer of myofibroblast differentiation. Exogenous

TGF β 1 induced cell spreading, stress fibers formation, and expression of EDA-FN and α-SMA (Figs. 2B, 2C and 4C), in agreement with data in the literature (15). In our experiments, SkQ1 did not affect the level of TGF β 1 mRNA or the total amount of TGF β 1 either in cell lysates (not shown) or in the culture medium (Fig. 6A). However, we detected a transient increase in the amount of *active* TGF β 1 after 1 h of incubation with SkQ1, followed by return to the basal level in the next 2–3 h (Fig. 6A). The concentration of the active TGF β 1 in samples with SkQ1 was 0.6 ng/ml. When added to the same concentration, exogenous TGF β 1 induced the typical myofibroblast differentiation (not shown). We observed induction of α-SMA expression by SkQ1 and Trolox, while these antioxidants partially decreased the effect of exogenous TGF β 1 (Fig. 6B).

Further evidence for activation of TGF β 1 in the SkQ1-treated fibroblasts came from measurements of SMAD2 phosphorylation. SMAD2 is a signaling protein that is phosphorylated directly by TGF β -receptor after TGF β 1 binding (13, 36). We showed that SMAD2 was phosphorylated 2–3 h after addition of SkQ1 (Fig. 6C). Trolox also induced phosphorylation of SMAD2, but NAC was ineffective, consistent with the absence of any NAC-induced expression of myofibroblast markers. To verify the role of TGF β 1 in the SkQ1-induced effects, we applied the TGF β 1 receptor I kinase inhibitor II. This inhibitor prevented the SkQ1-induced expression of myofibroblast markers (Fig. 4C).

To study the possible role of TGF β 1 in reorganization of actin cytoskeleton by the antioxidants, we applied the soluble receptor of TGF β 1 (TGF β RII). This receptor significantly decreased the basic level of phospho-cofilin and prevented phosphorylation of cofilin in response to SkQ1. Exogenous TGF β 1 also induced phosphorylation of cofilin, while inhibitor of the Rho pathway abrogated this effect (Fig. 5) in line with earlier observations (26, 38). These data indicate that activation of the Rho/ROCK/LIMK pathway by SkQ1 depends on TGF β 1. NAC induced cofilin phosphorylation and changes in cytoskeleton and morphology of fibroblasts that were similar to the effects of SkQ1 and Trolox (Figs. 2B and 5), but NAC did not induce TGF β 1 activation and signaling (Fig. 6C). This means that antioxidants can activate Rho by both TGF β 1-dependent and TGF β 1-independent mechanisms.

The culture medium where the SkQ1-treated fibroblasts were grown induced the same morphological changes and expression of myofibroblast markers as SkQ1 did (Figs. 7A and 7B). Addition of anti-TGF β 1 antibodies (Figs. 7A and 7B) into the conditioned medium completely abolished this effect. Thus, we conclude that self-maintaining of the myofibroblast differentiation initiated by SkQ1 is supported by autocrine stimulation of TGF β 1. This conclusion is consistent with an increase in the concentration of active TGF β 1 (but not total TGF β 1) in the conditioned medium. A similar effect was induced by Trolox, but not by NAC.




FIG. 6. SkQ1 induces activation of TGF β 1. Where indicated, 20 nM SkQ1, 200 μ M Trolox, or 5 mM NAC was added. (A) Active and total TGF β 1 in the culture medium (ELISA); (B) effects of Trolox (100 μ M, 30 min before TGF β 1) and SkQ1 (20 nM, 30 min before TGF β 1) on expression of α-SMA induced by added TGF β 1 (5 ng/ml, 3 days); (C) ratio of phospho-SMAD2/SMAD2 analyzed after 3 h of incubation with the antioxidants (Western blotting; actin was used as a loading control).




FIG. 7. Myofibroblast markers in HSCF treated with SkQ1 are supported in time by autocrine stimulation of TGF β 1. Conditioned medium was collected from HSCF culture treated with 20 nM SkQ1, 200 μ M Trolox, or 5 mM NAC for 7 days, and then the cells were grown for 4 days without antioxidants. Anti-TGF β 1 antibodies were added into the conditioned medium where indicated. (A) Fraction of α -SMA positive cells in the culture treated for 4 days with conditioned medium; (B) concentration of active and total TGF β 1 in the conditioned medium (ELISA).

Activation of TGFβ1 induced by SkQ1 is catalyzed by matrix metalloprotease 9

One of the mechanisms of activation of the latent $TGF\beta1$ complex involves matrix metalloprotease 9 (MMP9) (3, 40). SkQ1 (20 nM) and 0.1 mM Trolox rapidly (in 15–45 min) stimulated MMP9 (but not MMP2) in fibroblasts (Fig. 8A). Incubation of HSCF with SkQ1 simultaneously increased the content of the active form of MMP9 and its precursor, as revealed by zymography. We did not observe significant changes in the ratio of these two forms, indicating that SkQ1 induces secretion of MMP9 rather than its processing. In contrast, 5 mM NAC inhibited the basal MMP9 level. The




FIG. 8. Activation of TGF β 1 induced by SkQ1 depends on MMP9. (A) Zymography of MMP9 in the culture medium after 45 min incubation with 20 nM SkQ1, 200 μM Trolox, or 5 mM NAC. The ratio of mature MMP9 to its precursor was measured after densitometry of zymogramms; (**B**) effect of MMP inhibitors GM6001 (10 μM) and MMP9 inhibitor-I (100 nM) on SMAD2 phosphorylation induced by SkQ1 (20 nM, 3 h).

inhibitory effect of NAC on MMP9 activity was described earlier and attributed to docking to Zn^{2+} at the active site (9, 28). The absence of NAC-induced MMP9 increase correlates perfectly with the absence of TGF β 1 activation, SMAD2 phosphorylation, and myofibroblast marker expression by




FIG. 9. Regulation of myofibroblast differentiation by mitochondrial ROS.

this antioxidant (Figs. 4C and 6C). To test the necessity of MMP in TGF β 1 activation, we used the inhibitor of the MMP group (MMP-1, -2, -3, -8, -9) GM6001 (10 μ M, Millipore, Temecula, CA) and specific MMP9 inhibitor-I (100 nM, Merck, Whitehouse Station, NJ). Both agents prevented SkQ1-dependent stimulation of SMAD2 phosphorylation, indicating that MMP activity was critical for stimulation of TGF β 1 signaling (Fig. 8B). We suggested that MMP9 is a key effecter in our model, but we could not exclude the role of some other MMPs.

Discussion

Scavenging of ROS in mitochondria with the novel mitochondria-targeted antioxidant SkQ1 induced dramatic changes in the actin cytoskeleton, including stabilization of stress fibers and related focal adhesions (Figs. 2 and 3). These changes were accompanied by cell area enlargement and followed by expression of the major markers of myofibroblast differentiation EDA-FN and α -SMA (Fig. 4). The induction of myofibroblast differentiation is due to the antioxidant activity of SkQ1 in mitochondria. This follows from the facts that: (i) neither DPQ nor C₁₂TPP leads to myofibroblast differentiation; (ii) the uncoupler FCCP, which prevents accumulation of SkQ1 in mitochondria, blocks the SkQ-dependent transition; (iii) the traditional antioxidant Trolox induces myofibroblast differentiation, but at much higher concentration than SkQ1. The antioxidant NAC, in line with data published earlier (2), induced the same remodeling of actin cytoskeleton as Trolox and SkQ1 (Fig. 2B). However, NAC did not induce expression of myofibroblast differentiation markers (Fig. 4C). These data indicate that the antioxidants activate two separate signaling pathways, both resulting in changes in cell morphology. The further experiments showed that this complex transition is mediated by (a) stimulation of Rho-dependent signaling and (b) activation of extracellular TGF β 1 (Fig. 9).

The mitochondria-targeted antioxidant SkQ1 induced stabilization of stress fibers mediated by Rho-dependent phosphorylation and inactivation of the actin-depolymerizing protein cofilin. We found that cofilin is phosphorylated by LIMK1/2. This kinase was activated by Rho-dependent kinase ROCK via phosphorylation at Thr 508/505 (Fig. 5). Higher concentrations of NAC and Trolox induced the same effects. We suggest that mitochondrial ROS are preferentially responsible for modulation of Rho-dependent signaling. Similar observations were made in our previous study on mouse fibroblast cell line transformed by N-Ras (1). The mechanism of ROS-induced inhibition of Rho in Ras-transformed fibroblasts was recently described (34). This mechanism includes ROSdependent oxidation and inactivation of protein phosphatase LMW resulting in inhibition of Rho-GAP. Inhibition of Rho in this model prevented ROCK-dependent activation of LIMK, which phosphorylated cofilin. Perhaps SkQ1 and other antioxidants in our experiments inhibited the similar ROSdependent signaling. The effects of the mitochondria-targeted antioxidant indicate that mitochondrial ROS significantly contribute to Ras-induced changes of actin cytoskeleton and play the major role in regulation of actin dynamics in nontransformed fibroblasts. It seems possible that the effect of mitochondrial ROS is amplified by NOX1, since its expression can be activated by ROS produced in mitochondria (14).

The incubation of fibroblasts with SkQ1 resulted in expression of EDA-FN and α-SMA, indicating myofibroblast differentiation (Fig. 4). We suggest that the effect of SkQ1 is mediated by TGF β 1. We found that SkQ1 induces temporary activation of TGF β 1, followed by SMAD2 phosphorylation (Fig. 6). Activation of TGF β 1 was not accompanied by activation of its expression, since the total amount of this protein was not increased. It is known that TGF β 1 forms a large latent complex bound to the extracellular matrix. The mechanisms of its activation are investigated and intensively discussed (3). One of the major proteolytic activators of latent TGF β 1 is MMP9 (3, 40). SkQ1 and Trolox induced rapid accumulation of MMP9 in the culture medium (Fig. 8A). We did not observe a significant effect of SkQ1 on the ratio of the active form of MMP9 to its precursor, indicating that SkQ1 induces secretion of MMP9. These data suggest that the suppression of exocytosis by excessive ROS (25) was prevented by SkQ1 and Trolox. These antioxidants could stimulate general secretion, while the inhibitory effect of NAC on the MMP9 activity could be based on direct interaction with the metal in the active site of the MMP (9, 28). Using the specific inhibitor of MMP9, we confirmed that this protease activity was necessary for SkQ1induced activation of TGF β 1-dependent signaling (Fig. 8B).

TGF β 1 is known to trigger a plethora of signaling events, both SMAD-dependent and independent. SMAD-dependent expression of EDA-FN and α -SMA was critical for myofibroblast differentiation induced by SkQ1. At the same time, SMAD-independent signaling is involved in activation of the RhoA/ROCK/LIMK1/2/cofilin pathway, leading to stabilization of stress fibers and related focal adhesions (13, 26, 38). Binding of TGF β 1 in the medium by soluble receptor TGF β RII significantly reduced cofilin phosphorylation induced by SkQ1, indicating the key role of TGF β 1 (Fig. 5). The same pathway was induced by NAC, which does not stimulate TGF β 1, indicating the direct activation of Rho by ROS scavenging.

The observed stimulation of TGF β 1 by SkQ1 had two phases: the first was accomplished 1 h after addition of SkQ1 (Fig. 6A), while the second developed during 7 days (Fig. 7B). The experiments with conditioned medium demonstrated that TGF β 1 activated in the second phase induced an autocrine loop that can support myofibroblast phenotype. The amount of MMP9 in the culture medium drops below the initial level 7 days after SkQ1 treatment (not shown), so the high level of active TGF β 1 in the culture was supported by another mechanism. Activation of TGF β 1 in myofibroblast culture could be associated with an increase in adhesion to ECM and mediated by a local integrin-dependent transition, as described earlier (6, 39), rather than by proteolysis.

The dynamics of myofibroblast differentiation induced by SkQ1 can be divided into the earliest activation of RhoA/ROCK/LIMK1/2-signaling, which depends on TGF β 1, and later actin stress fiber formation and maturation of focal adhesions. We observed an enhancement of EDA-FN expression after 2–3 days, and we detected α -SMA expression at day 4, with further increase after 7-9 days of incubation. All these events were described earlier in more detail for myofibroblast differentiation induced by TGF β 1 (15, 19, 21, 33). It seems important that the dynamics of these steps was very similar in our experiments with the antioxidants and in the studies of TGF β 1-induced differentiation. It was shown earlier that ROS are involved in TGF β 1-dependent signaling. In particular, a member of the NOX family, NOX4, has been implicated in cardiac myofibroblast differentiation from fibroblast precursors (12). In our model, antioxidants both induced activation of TGF β 1 and partially suppressed the effect of added TGF β 1 (Fig. 6B). Future studies on physiological functions of the cells differentiated by SkQ1 (such as cell contraction) would show the degree of myofibroblast maturation in vitro. The possible induction of myofibroblast differentiation by SkQ1 in vivo could contribute to stimulation of dermal wound healing, and these experiments are ongoing in our laboratory.

In general, we conclude that scavenging of ROS in mitochondria with the novel mitochondria-targeted antioxidant SkQ1 induces Rho-dependent reorganization of actin cytoskeleton and TGF β 1-dependent myofibroblast differentiation.

Acknowledgments

This work was supported by Russian Foundation for Basic Research grants 07-04-00335, 09-04-00667 and Mitotech LLC. We thank M. Domninskaya for technical assistance, Dr. R. Zinovkin and Dr. M. Skulachev for careful reading of the manuscript and discussion, and Dr. S. Golyshev for assistance with microscopy.

Author Disclosure Statement

No competing financial interests exist.

References

Agapova LS, Chernyak BV, Domnina LV, Dugina VB, Efimenko AY, Fetisova EK, Ivanova OY, Kalinina NI, Khromova NV, Kopnin BP, Kopnin PB, Korotetskaya MV, Lichinitser MR, Lukashev AL, Pletjushkina OY, Popova EN, Skulachev MV, Shagieva GS, Stepanova EV, Titova EV,

- Tkachuk VA, Vasiliev JM, and Skulachev VP. Mitochondriatargeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. *Biochemistry* (*Mosc*) 73: 1300–1316, 2008.
- Alexandrova AY, Kopnin PB, Vasiliev JM, and Kopnin BP. ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res 312: 2066–2073, 2006.
- 3. Annes JP, Munger JS, and Rifkin DB. Making sense of latent TGFbeta activation. *J Cell Sci* 116: 217–224, 2003.
- 4. Antonenko YN, Avetisyan AV, Bakeeva LE, Chernyak BV, Chertkov VA, Domnina LV, Ivanova OY, Izyumov DS, Khailova LS, Klishin SS, Korshunova GA, Lyamzaev KG, Muntyan MS, Nepryakhina OK, Pashkovskaya AA, Pletjushkina OY, Pustovidko AV, Roginsky VA, Rokitskaya TI, Ruuge EK, Saprunova VB, Severina, II, Simonyan RA, Skulachev IV, Skulachev MV, Sumbatyan NV, Sviryaeva IV, Tashlitsky VN, Vassiliev JM, Vyssokikh MY, Yaguzhinsky LS, Zamyatnin AA, Jr., and Skulachev VP. Mitochondriatargeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and *in vitro* studies. *Biochemistry* (Mosc) 73: 1273–1287, 2008.
- Antonenko YN, Roginsky VA, Pashkovskaya AA, Rokitskaya TI, Kotova EA, Zaspa AA, Chernyak BV, and Skulachev VP. Protective effects of mitochondria-targeted antioxidant SkQ in aqueous and lipid membrane environments. J Membr Biol 222: 141–149, 2008.
- Asano Y, Ihn H, Yamane K, Jinnin M, and Tamaki K. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. *Am J Pathol* 168: 499–510, 2006.
- 7. Bakeeva LE, Barskov IV, Egorov MV, Isaev NK, Kapelko VI, Kazachenko AV, Kirpatovsky VI, Kozlovsky SV, Lakomkin VL, Levina SB, Pisarenko OI, Plotnikov EY, Saprunova VB, Serebryakova LI, Skulachev MV, Stelmashook EV, Studneva IM, Tskitishvili OV, Vasilyeva AK, Victorov IV, Zorov DB, and Skulachev VP. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 2. Treatment of some ROS- and age-related diseases (heart arrhythmia, heart infarctions, kidney ischemia, and stroke). Biochemistry (Mosc) 73: 1288–1299, 2008.
- 8. Bamburg JR and Wiggan OP. ADF/cofilin and actin dynamics in disease. *Trends Cell Biol* 12: 598–605, 2002.
- 9. Bogani P, Canavesi M, Hagen TM, Visioli F, and Bellosta S. Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. *Biochem Biophys Res Commun* 363: 651–655, 2007.
- Chiarugi P. From anchorage dependent proliferation to survival: Lessons from redox signalling. *IUBMB Life* 60: 301– 307, 2008.
- Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, Galeotti T, and Ramponi G. Reactive oxygen species as essential mediators of cell adhesion: The oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. *J Cell Biol* 161: 933–944, 2003.
- Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900–907, 2005
- Derynck R and Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. *Nature* 425: 577–584, 2003.

- 14. Desouki MM, Kulawiec M, Bansal S, Das GM, and Singh KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. *Cancer Biol Ther* 4: 1367–1373, 2005.
- Dugina V, Fontao L, Chaponnier C, Vasiliev J, and Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci 114: 3285–3296, 2001.
- Dunn GA and Brown AF. Alignment of fibroblasts on grooved surfaces described by a simple geometric transformation. J Cell Sci 83: 313–340, 1986.
- 17. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. *J Pathol* 200: 500–503, 2003.
- 18. Gasparian ME, Ostapchenko VG, Yagolovich AV, Tsygannik IN, Chernyak BV, Dolgikh DA, and Kirpichnikov MP. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase. *Biotechnol Lett* 29: 1567–1573, 2007.
- 19. Hinz B. Formation and function of the myofibroblast during tissue repair. *J Invest Dermatol* 127: 526–537, 2007.
- 20. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton–Piallat ML, and Gabbiani G. The myofibroblast: One function, multiple origins. *Am J Pathol* 170: 1807–1816, 2007.
- 21. Ho FM, Liu SH, Lin WW, and Liau CS. Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells. *J Cell Biochem* 101: 442–450, 2007.
- Izyumov DS, Avetisyan AV, Pletjushkina OY, Sakharov DV, Wirtz KW, Chernyak BV, and Skulachev VP. "Wages of fear": Transient threefold decrease in intracellular ATP level imposes apoptosis. *Biochim Biophys Acta* 1658: 141–147, 2004.
- 23. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, and Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. *J Biol Chem* 276: 4588–4596, 2001.
- 24. Kleiner DE and Stetler–Stevenson WG. Quantitative zymography: Detection of picogram quantities of gelatinases. *Anal Biochem* 218: 325–329, 1994.
- Lowenstein CJ and Tsuda H. N-ethylmaleimide-sensitive factor: A redox sensor in exocytosis. *Biol Chem* 387: 1377– 1383, 2006.
- Moustakas A and Stournaras C. Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts. *J Cell Sci* 112: 1169–1179, 1999.
- 27. Neroev VV, Archipova MM, Bakeeva LE, Fursova A, Grigorian EN, Grishanova AY, Iomdina EN, Ivashchenko Zh N, Katargina LA, Khoroshilova–Maslova IP, Kilina OV, Kolosova NG, Kopenkin EP, Korshunov SS, Kovaleva NA, Novikova YP, Philippov PP, Pilipenko DI, Robustova OV, Saprunova VB, Senin, II, Skulachev MV, Sotnikova LF, Stefanova NA, Tikhomirova NK, Tsapenko IV, Shchipanova AI, Zinovkin RA, and Skulachev VP. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry (Mosc) 73: 1317–1328, 2008.
- 28. Pei P, Horan MP, Hille R, Hemann CF, Schwendeman SP, and Mallery SR. Reduced nonprotein thiols inhibit activation and function of MMP-9: Implications for chemoprevention. *Free Radic Biol Med* 41: 1315–1324, 2006.
- 29. Pletjushkina OY, Fetisova EK, Lyamzaev KG, Ivanova OY, Domnina LV, Vyssokikh MY, Pustovidko AV, Vasiliev JM, Murphy MP, Chernyak BV, and Skulachev VP. Long-distance apoptotic killing of cells is mediated by hydrogen

- peroxide in a mitochondrial ROS-dependent fashion. *Cell Death Differ* 12: 1442–1444, 2005.
- Pletjushkina OY, Lyamzaev KG, Popova EN, Nepryakhina OK, Ivanova OY, Domnina LV, Chernyak BV, and Skulachev VP. Effect of oxidative stress on dynamics of mitochondrial reticulum. *Biochim Biophys Acta* 1757: 518–524, 2006.
- Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, and Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123–127, 2005.
- Rokitskaya TI, Klishin SS, Severina, II, Skulachev VP, and Antonenko YN. Kinetic analysis of permeation of mitochondria-targeted antioxidants across bilayer lipid membranes. J Membr Biol 224: 9–19, 2008.
- Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, and Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142: 873–881, 1998.
- 34. Shinohara M, Shang WH, Kubodera M, Harada S, Mitsushita J, Kato M, Miyazaki H, Sumimoto H, and Kamata T. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by down-regulating Rho. J Biol Chem 282: 17640–17648, 2007.
- 35. Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, Kopnin BP, Korshunova GA, Lichinitser MR, Obukhova LA, Pasyukova EG, Pisarenko OI, Roginsky VA, Ruuge EK, Senin, II, Severina, II, Skulachev MV, Spivak IM, Tashlitsky VN, Tkachuk VA, Vyssokikh MY, Yaguzhinsky LS, and Zorov DB. An attempt to prevent senescence: A mitochondrial approach. *Biochim Biophys Acta* 1787: 437–461, 2009.
- 36. ten Dijke P and Hill CS. New insights into TGF-beta-Smad signalling. *Trends Biochem Sci* 29: 265–273, 2004.
- Thannickal VJ, Day RM, Klinz SG, Bastien MC, Larios JM, and Fanburg BL. Ras-dependent and -independent regulation of reactive oxygen species by mitogenic growth factors and TGF-beta1. FASEB J 14: 1741–1748, 2000.
- Vardouli L, Moustakas A, and Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-beta. *J Biol Chem* 280: 11448–11457, 2005.
- 39. Wipff PJ, Rifkin DB, Meister JJ, and Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. *J Cell Biol* 179: 1311–1323, 2007.
- 40. Yu Q and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. *Genes Dev* 14: 163–176, 2000.

Address correspondence to:

Dr. Boris V Chernyak

Belozersky Institute

Moscow State University,

Leninskie Gory 1, Bldg. 40

Moscow 119991

Russia

E-mail: bchernyak@genebee.msu.ru

Date of first submission to ARS Central, October 13, 2009; date of final revised submission, April 26, 2010; date of acceptance, May 1, 2010.

Abbreviations Used

 α -SMA = smooth muscle actin

 $C_{12}TPP = dodecyltriphenylphosphonium$

CM-DCF-DA = 5,6-chloromethyl-2',7'-

dichlorodihydrofluorescein diacetate

DPQ = decylplastoquinone

ECM = extracellular matrix

EDA-FN = a fibronectin isoform

HSCF = human subcutaneous fibroblasts

MMP9 = matrix metalloprotease 9

NAC = N-acetylcysteine

NOX1 = NADPH oxidase 1

ROS = reactive oxygen species

SkQ1 = 10-(6'-plastoquinonyl)

decyltriphenylphosphonium

SkQR1 = 10-(6'-plastoquinonyl)

decylrhodamine 19

 $TGF\beta 1 = transforming growth factor \beta 1$

 $TGF\beta$ -LAP/LTBP = $TGF\beta$ 1 large latent complex

 $TGF\beta RII = recombinant human soluble receptor$

of TGF β 1